Back

The Drug-Induced Respiratory Disease Website and App

Rivaroxaban

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
I.b

Pneumonitis (interstitial lung disease/ILD)

III - Pulmonary/alveolar/airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

V - Pleural and/or pericardial involvement

V.e

Hemothorax - Serosanguineous pleural effusion
V.n

Hemopericardium - Bloody pericardial effusion

VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement

VIII.b

Hematoma of/around central airway wall potentially causing UAO
VIII.q

Tongue involvement (edema, glossitis, hematoma)

X - Systemic/Distant conditions, syndromes and reactions

X.a

DRES syndrome - DRESS-like reaction
X.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
X.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)
X.s

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

XII - Cardiovascular involvement / toxicity

XII.k

Constrictive pericarditis - Pericardial thickening

XV - Pathology

XV.ci

Path: Fibrinous pericarditis